Perrigo

Ecrit par Alain Zeitoun sur . Publié dans , ,

Perrigo Company is the largest manufacturer of private label over-the-counter pharmaceuticals in the United States.[2] The company’s shares are traded on the NYSE and the Tel Aviv Stock Exchange; as a result of the merger with Agis Industries the company is a constituent of the TA-25 Index. Perrigo is the only non-Israeli company on the TA-25.

Perrigo Company, through its wholly owned subsidiaries, engages in the manufacture and sale of consumer healthcare products, generic prescription drugs, active pharmaceutical ingredients (API), and consumer products primarily in the United States, Australia, Israel, Europe, India and Mexico.

History

Black and white photo of L.Perrigo Co. Aspirin tablets

The L. Perrigo Company was founded in 1887 in Allegan, Michigan, by Luther and Charles Perrigo, who ran a country general store .[3] In 1991 Perrigo had an Initial public offering on NASDAQ.

 

In March 2005 the firm acquired Agis Industries Ltd. (TASE:AGIS), an Israel based generic pharmaceuticals company in an $850 million transaction. Agis was founded in 1983 by Moshe (Mori) Arkin who developed his father’s small drug import business into a multinational generic pharmaceutical company. As a result of the acquisition Arkin owns 9% of Perrigo, and was appointed as Vice Chairman of the company.[4]

 

Acquisitions

On 9 January 2008, the firm acquired Galpharm Healthcare, Ltd., a supplier of over-the-counter store brand pharmaceuticals in the United Kingdom.[5] On 16 September 2008, the firm acquired J.B. Laboratories .[6] On 6 October 2008, it acquired Laboratorios Diba S.A., enabling the company to market its products in Mexico.[7] On 13 November 2008, ity acquired Unico Holdings, a manufacturer of store brand pediatric electrolytes, enemas and feminine hygiene products for retail consumers in the U.S.[8]

On 1 March 2010, the firm acquired Orion Laboratories Pty, Ltd. a supplier of over-the-counter (OTC) store brand pharmaceutical products in Australia and New Zealand.[9] On 23 March 2010, it acquired PBM Holdings, Inc.,a producer of over-the-counter store brand infant formula and baby foods in the United States, Canada, Mexico and China.[10]

On 20 January 2011, the firm announced that it would acquire Paddock Laboratories Inc., with the deal expected to close in fiscal 2012.[11] On 29 July 2013, the firm announced that it would acquire Élan a major drugs firm based in Dublin.[12][13]

 

Segments

The company operates in three segments; Consumer Healthcare, Rx Pharmaceuticals, and Active Pharmaceutical Ingredients. The Consumer Healthcare segment produces over-the-counter pharmaceutical and nutritional products in the United States, the United Kingdom, and Mexico. This segment offers analgesic, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, first aid, antacids, hemorrhoidal remedies, motion sickness, sleep aid products, feminine hygiene products, vitamin, and nutritional supplement products.

The Rx Pharmaceuticals segment produces generic prescription drugs in the United States. This segment provides creams, ointments, lotions, gels, and solutions, as well as nasal sprays, foams, and transdermal devices.

The Active Pharmaceutical Ingredients segment produces pharmaceutical ingredients in Israel with sales to customers worldwide. The company also offers cosmetics, toiletries, detergents, manufactured and imported pharmaceutical products, and medical diagnostic products. The company’s customers include national and regional retail drug, supermarket, wholesalers, and mass merchandise chains.

 

Management

Joseph C. Papa is the Chief Executive Officer and President.[14]

 

Awards

101 Best and Brightest Companies to Work For of West Michigan awarded Perrigo overall “Best of the Best” for 2009.[15]

In 2010 Perrigo was named one of the top 100 Fastest-Growing Companies by Fortune Magazine.[16]

Iscar Metalworking

Ecrit par Alain Zeitoun sur . Publié dans ,

Iscar Metalworking (Hebrew: ישקר בע »מ ‎) is an Israeli toolmaking company affiliated with the IMC. In 2006, Warren Buffett purchased an 80 percent stake in the company. On May 1, 2013, Buffett bought the remaining 20% of Iscar for $2.05 billion, vowing however, to keep the company in Israel.[1] It is one of Berkshire Hathaway‘s largest non-insurance companies.[2]

History

The company was founded in 1952 in a wooden garage behind the home of Stef Wertheimer in Israel. After several years of steady expansion, the company headquarters moved to its current site in the Tefen Industrial Zone, situated in Israel’s Western Galilee.

Iscar has expanded from a single marketing and manufacturing facility in Israel to a multinational company with representation in over 50 countries. Its production facilities are highly automated; at night, a single employee runs the plants on a computer, from home.[3]

In May 2006, Berkshire Hathaway, chaired by Warren Buffett, purchased an 80% stake in Iscar for US$4 billion. It was the first time in Berkshire’s history that it acquired a company based outside of the United States.

In 2008, Mr. Buffett called the acquisition of Iscar a « dream deal » that surpassed all his expectations. He personally attended the inauguration of a new production plant in Dalian, China.[4]

The CEO of Iscar is Jacob Harpaz. The company has 140 subsidiaries in 65 countries.[5]In a 2012 letter to shareholders, Iscar’s managers were described as « brilliant strategists and operators, » and Buffet praised the sales growth and performance of the company as « unique in its industry. » [6]

International Offices

Iscar has production facilities in Israel, France, Argentina, Germany, Hungary, Brazil, Italy, The United States of America, The Netherlands, Spain, South Korea, Switzerland, Turkey and the United Kingdom.[7]

Teva Pharmaceuticals

Ecrit par Alain Zeitoun sur . Publié dans , , ,

Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע »מ‎) is an international pharmaceutical company headquartered in Petah Tikva, Israel. It specializes in generic and proprietary pharmaceuticals and active pharmaceutical ingredients. It is the largest generic drug manufacturer in the world[2] and one of the 15 largest pharmaceutical companies worldwide.[3]

Teva’s facilities are located in Israel, North America, Europe, and South America. Teva is a member of both the New York Stock Exchange and the Tel Aviv Stock Exchange.

Eli Hurwitz was the CEO of Teva from 1976 to 2002, and chairman of the board until his death in 2011.[4][5]

Since May 2012 Jeremy Levin has been the CEO.

History

Worker at Assia plant in the 1930s

Teva plant, Har Hotzvim, Jerusalem

Teva’s earliest predecessor was Salomon, Levin, and Elstein Ltd., a wholesale distributor based in Jerusalem that was founded in 1901. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva (« Nature » in Hebrew), Assia, and Zori. In 1951, Teva raised capital through the newly founded Tel-Aviv Stock Exchange.

In 1964, Assia and Zori merged and acquired a controlling interest in Teva. In 1976, these three companies merged into the modern Teva Pharmaceutical Industries Ltd. In 1980, Teva continued to follow its vision of becoming one of the world’s biggest pharmaceutical companies by acquiring Ikapharm, then Israel’s second largest drug manufacturer.[6]

In 1982, Teva was granted approval by the U.S. Food and Drug Administration (FDA) for its Kfar Saba manufacturing plant, an essential milestone for marketing pharmaceuticals in the USA.

In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007.[7] Teva entered the Japanese market in 2005, and in 2008 established a generics joint venture with Kowa.[8]

In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. Teva acquired its U.S. rival Ivax Corporation in January 2006, Barr in 2007 and Ratiopharm in 2010.

In 2010, Teva announced that it would be building its main distribution center for the Americas in Philadelphia, PA and was considering opening its US headquarters in the area.[7] In 2010, it had 39,660 employees. In Israel, the number of workers rose 7.5% to 6,774.[9] In March 2010, Teva acquired German-based company Ratiopharm in a nearly $5 billion deal, significantly expanding its European coverage.[10][11][12] In May 2011 Teva announced it will purchase Cephalon for US$6.8 billion as part of its effort to expand its presence in the proprietary pharmaceuticals sector.

Within Teva operates Teva Active Pharmaceutical Ingredients (TAPI) as a stand-alone business unit. On top of supplying a major share of Teva’s own needs, the TAPI division is an active competitor in world markets. In 2009, TAPI’s sales to third parties totaled $565 million, and in 2010 sales rose by 13% to a total of $641 million.

Mergers and acquisitions

On December 23, 2008, Teva acquired Barr Pharmaceuticals for US$7.5 billion, making Barr and Pliva (which Barr bought earlier) part of Teva.[13] On March 18, 2010, Teva announced that it planned to acquire German generic Ratiopharm for US$5 billion. The deal was completed in August 2010.[7]

In May 2011, Teva bought Cephalon for US$6.8 billion.[14] Shortly after this announcement, Teva announced the ¥40 billion purchase of a majority stake in the Japanese generic drug company Taiyo Pharmaceutical Industry, a move to secure a Japan-local production facility.[8] Teva completed the $934 million acquisition on July 2011.[15]

Research and Development

Copaxone, a Teva patented drug

Teva holds a patent on multiple drugs including: Copaxone (for the treatment of multiple sclerosis), now the world’s best selling MS drug, and Azilect (sold as Agilect in some countries) for treatment of Parkinson’s disease.

In June 2006, Teva received from the FDA a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug in all strengths except 80 mg. Teva presently[when?] competes with the maker of brand-name Zocor, Merck & Co.; Ranbaxy Laboratories, which has 180-day exclusivity for the 80 mg strength; and Dr. Reddy’s Laboratories, whose authorized generic version (licensed by Merck) is exempt from exclusivity.

In June 2010, the company announced it would discontinue its production of propofol, a major sedative estimated to be used in 75% of all US anesthetic procedures.[16]

Legal issues

On June 25, 2010, Bayer sued Teva for falsely claiming that Gianvi, Teva’s Generic of Yaz, was « stabilized by betadex as a clathrate. »[17] The lawsuit stems from Bayer’s US patent, 5798338, on the binding and preservative agents that were not in fact present in Gianvi. « In the preparation of such low-dosed dosage forms, strong fluctuations of the active ingredient concentrations in the dosage units occur almost unavoidably (inadequate content uniformity), which manifest themselves more strongly, the smaller the amount of the active ingredient. It has now been found that the drawbacks that are observed especially in the preparation and storage of dosage forms which contain low-dosed steroidal sex hormones can be avoided, at least to a large extent, if dosage forms are prepared that contain powdery cyclodextrin clathrates of these active ingredients. »[18] The settlement of the lawsuit resulted in Teva changing its product marketing to remove the claim that it used the same ingredients as Yaz.[19][dead link] Bayer’s patent is on a method specifically designed to prevent oxidative degradation of the estrogen.

Keter Plastic

Ecrit par Alain Zeitoun sur . Publié dans ,

Keter Plastic Ltd
IndustryPlastic Manufacturing
Founded1948
HeadquartersHerzliya, Israel
ProductsHousehold and Garden consumer goods
EmployeesOver 1500
Websitewww.keter.com

 

 

 

Keter Plastic Ltd. (Hebrew: כתר פלסטיק‎) is an Israeli manufacturer and marketer of resin-based household and garden consumer products. The company, established in 1948, has a chain of retail stores throughout Israel and operates 29 plants in Israel, Europe and the United States. It has 2 factories located in Israeli settlements in the Palestinian territories.[1][2] Keter products are marketed worldwide.

History

 

The Keter brand evolved from a small workshop established in Jaffa in 1948, specializing in the production of plastic combs, toys and housewares. In 1971, Joseph Sagol bought out his partners’ shares in the workshop, and the Sagol family has owned Keter ever since.[3] Sagol later handed the management of the company over to his sons, Sami and Itzhak.

 

Since 1978, Keter Plastic has expanded its home product lines to include garden sheds, toolboxes, bathroom cabinets, backyard playhouses for children, and more – all made of resin.

 

In 1991, Keter acquired competitor L.M. Lipski.[3]

 

In 2011, Keter won Red Dot Design Award for its RealBarrow, a heavy-duty wheelbarrow with an L-shape « bulldozer » shovel.[4]

 

Products

 

Keter manufactures a wide range of household and garden resin-based products, plastic storage solutions, and outdoor furniture: outdoor furniture, lifestyle and gardening, outdoor storage products, tool storage, kids, indoor storage, home organization and bath. It is one of Israel’s largest manufacturers of plastic outdoor and garden furniture.[5]

 

Awards

 

  • Israeli Industrial Design Award (2009)
  • Red Dot Design Award, Product Design (2010)
  • ID Annual Design Review (2010)
  • DIY Product of the Year (2010)
  • Red Dot Design Award, Product Design (2011)[4]

AHAVA

Ecrit par Alain Zeitoun sur . Publié dans ,

From Wikipedia, the free encyclopedia
Ahava Dead Sea Laboratories, Limited
TypePrivate
IndustryCosmetics
Founded1988
HeadquartersHolonIsrael
ProductsSkin care
Revenue$150 million
Employees200
Websitehttp://www.ahava.com/

Ahava factory

Ahava Dead Sea Laboratories, Limited (Hebrew: אהבה‎, Love) is an Israeli cosmetics company that manufactures skin care products made of mud and mineral-based compounds from the Dead Sea. The company’s administrative headquarters are located in Holon, while the main manufacturing plant and showroom are in Mitzpe Shalem,[a 1] an Israeli settlement and kibbutz located on the Dead Sea in the West Bank.[1][2] The company has flagship stores in Israel, Germany, Hungary, the Philippines and Singapore.[3] As of 2010, Ahava income was more than US$150 million a year.[4] Ahava products have caused controversy, as critics say the company uses natural resources of occupied Palestinian territory,[5] and that the products are incorrectly labeled as made in Israel.[6][7]

History

Ziva Gilad, a spa technician, came up with the idea of marketing Dead Sea mud after watching women tourists scooping up the mud to take home.[8] Ahava was founded in 1988 as a single stand selling bottles of body scrub to tourists, generating $1 million that year.[9]

Ahava’s shareholders include Hamashbir Holdings, Gaon Holdings, Kibbutz Ein GediKibbutz Mitzpe Shalem and Kibbutz KalyaKibbutz Mitzpe Shalem and Kibbutz Kalya are located north of the Green Line, in the West Bank.[10]

In 2009 Ahava took on new shareholder Shamrock Holdings, the Walt Disney Family’s investment arm, which purchased 20% of Ahava Dead Sea Laboratories from its existing shareholders[11][12] The company has 200 employees, 180 of them in Israel.[12]

Models wearing and distributing Ahava products atNew York Fashion Week in 2009

In 2009, the company reported sales of nearly $150 million a year. In the United States, the largest overseas market for Ahava products, the company signed distribution deals with Lord & TaylorNordstrom and the beauty-supply chain Ulta.[8]

Ahava is the only cosmetics company licensed by the Israeli government to mine raw materials at the Dead Sea.[8] On the Jordanian side of the Dead Sea, there are approximately fifty small companies producing cosmetics, but only 15 have a global presence. Israel has imported raw materials for its Dead Sea mud cosmetics from Jordan since 1994.[4]

In 2011, Elana Drell Szyfer, former Senior Vice President of Global Marketing for Estee Lauder, was appointed general manager of Ahava North America.[13]

Products

Ahava product lines include a basic product for all skin types; other products for dry, sensitive skin and for men’s skin; and anti-aging products for face and body.[14] Product lines include hand cream, foot cream, facial cleanser, body milk, facial nourishing cream, facial moisturizer, moisturizing shower cream and body cream.[15] Some products claim to use citrus and citrus products as a source of vitamins and minerals.[14]

Dead Sea mud, alone or in combination with other ingredients, is believed to have benefits for deep cleansing and stimulation of the skin. Minerals extracted from Dead Sea water such as calcium, magnesium and potassium, are said to improve the metabolism, stimulate circulation and aid in the natural repair of cells.[16] In 2009, Ahava Dermud range of skincare products has been shown to have protective, anti-oxidant and anti-inflammatory properties that can antagonize biological effects of UVB radiation on skin, reducing skin photodamage and photoaging, and reducing oxidative stress and inflammation in skin pathologies.[17]

Therapy with mud packs for conditions such as osteoarthritis is relatively expensive and requires the assistance of a therapist and a treatment room. In the wake of these limitations, Ahava developed mud compresses used in the home which are heated in a microwave oven or a pot of hot water and placed over painful joints. A clinical research by the Ben Gurion University of the Negev, supported in part by a grant from « Ahava », has concluded that the group treated with natural mud compresses had a reduction of 20% or more in Knee Osteoarthritis pain scores at treatment completion, at one month, and at three months, compared to the control group.[18]

Embracing the trend toward more natural ingredients in cosmetics, Ahava purifies its own water and, according to the company, employs minimally invasive techniques to harvest mud and minerals. Ingredients are not tested on animals and Ahava products are packaged in recyclable containers.[8]

Dans la Presse

Haaretz : Ahava cosmetics denies it will be hit by EU’s new sanctions

South Africa to ban labeling Ahava as made in Israel